Advanced Lung Non-Small Cell Carcinoma, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Conditions
Brief summary
This phase II trial studies how well docetaxel works with or without bintrafusp alfa in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Chemotherapy drugs, such as docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with bintrafusp alfa, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving docetaxel and bintrafusp alfa in combination may work better in treating non small-cell lung cancer compared to docetaxel alone.
Detailed description
PRIMARY OBJECTIVE: I. To compare the progression-free survival (PFS) of bintrafusp alfa in combination with docetaxel versus (vs) docetaxel alone. SECONDARY OBJECTIVES: I. To evaluate overall survival of bintrafusp alfa in combination with docetaxel vs docetaxel alone. II. To evaluate overall response rates of bintrafusp alfa in combination with docetaxel vs docetaxel alone. III. To evaluate duration of response of bintrafusp alfa in combination with docetaxel vs docetaxel alone. IV. To evaluate the safety of bintrafusp alfa in combination with docetaxel vs docetaxel alone. CORRELATIVE RESEARCH OBJECTIVES: I. To evaluate PD-L1, TGF-beta, and TMB as potential predictive markers of clinical response in tumor biopsies and in plasma. II. To evaluate biomarkers associated with inhibition of TGF-beta and PD-L1. III. To evaluate the changes in immune system using mass cytometry in response to TGF-beta and PD-L1 inhibition. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive docetaxel intravenously (IV) over 1 hour and bintrafusp alfa IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bintrafusp alfa IV over 60 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive docetaxel IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may crossover to Arm I and receive bintrafusp alfa alone. After completion of study treatment, patients are followed up at 30 days and then every 3 months for 5 years.
Interventions
DRUGBintrafusp Alfa
Given IV
DRUGDocetaxel
Given IV
Sponsors
Mayo Clinic
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>= 18 years * Histological confirmation of non-small cell lung cancer (NSCLC) with advanced disease * Prior treatment required: * Anti-PD1/PD-L1 agent in combination with platinum-based chemotherapy * Measurable disease * NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * Hemoglobin \>= 9.0 g/dL (obtained =\< 14 days prior to registration) * Absolute neutrophil count (ANC) \>= 1500/mm\^3 (obtained =\< 14 days prior to registration) * Platelet count \>= 100,000/mm\^3 (obtained =\< 14 days prior to registration) * Total bilirubin =\< upper limit of normal (ULN) (obtained =\< 14 days prior to registration) * Alanine aminotransferase (ALT/serum glutamate pyruvate transaminase \[SGPT\]) and aspartate transaminase (AST/serum glutamic-oxaloacetic transaminase \[SGOT\]) =\< 1.5 x ULN (obtained =\< 14 days prior to registration) * Alkaline phosphatase \<= 2.5 x ULN (obtained =\< 14 days prior to registration) * Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =\< 1.5 x ULN OR if patient is receiving anticoagulant therapy INR or aPTT is within target range of therapy (obtained =\< 14 days prior to registration) * Calculated creatinine clearance \>= 30 ml/min using the Cockcroft-Gault formula (obtained =\< 14 days prior to registration) * Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only * NOTE: If a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Willing to use birth control as follows: * If able to become pregnant: Willing to use birth control during treatment and for 6 months after last dose of docetaxel and/or bintrafusp alfa, whichever is later * If able to father a child: Willing to use birth control with partners able to become pregnant during treatment and for 3 months after last dose of docetaxel and/or bintrafusp alfa, whichever is later * Provide written informed consent * Willingness to provide mandatory blood specimens for correlative research * Willingness to provide mandatory tissue specimens for correlative research * Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study) * CROSSOVER ELIGIBILITY: Documented disease progression =\< 28 days prior to crossover registration * CROSSOVER ELIGIBILITY: No contraindications to bintrafusp alfa at the time of crossover registration * CROSSOVER ELIGIBILITY: Patient and physician agree to try crossover treatment with bintrafusp alfa * CROSSOVER ELIGIBILITY: Provide written informed consent
Exclusion criteria
* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: * Pregnant persons * Nursing persons * Persons of childbearing potential who are unwilling to employ adequate contraception * Any of the following prior therapies: * Surgery =\< 4 weeks prior to registration * Chemotherapy =\< 4 weeks prior to registration * Received single agent anti-PD1/PD-L1 as first line therapy for metastatic disease * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Or psychiatric illness/social situations that would limit compliance with study requirements * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * Other active malignancy =\< 5 years prior to registration * EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix * NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer * History of myocardial infarction =\< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias * Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases are excluded, with the following exceptions: * Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met: * Evaluable or measurable disease outside the CNS * No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm) * No history of intracranial hemorrhage or spinal cord hemorrhage * No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted * No neurosurgical resection or brain biopsy =\< 28 days prior to registration * Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following: * Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study * No stereotactic radiation or whole-brain radiation =\< 28 days prior to registration * Screening CNS radiographic study \>= 4 weeks from completion of radiotherapy and \>= 2 weeks from discontinuation of corticosteroids * History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins * History or current evidence of bleeding disorder, including bleeding diathesis, i.e., any hemorrhage/bleeding event of Common Terminology Criteria for Adverse Events (CTCAE) grade \>= 2 in =\< 28 days prior to registration * Taking oral prednisone of \>= 10 mg daily or equivalent * Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease. Notes: * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \[HBsAg\] test and a positive anti-HBc \[antibody to hepatitis B core antigen\] antibody test) are eligible * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA) * History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis. Notes: * Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible * Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible * Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: * Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations * Rash must cover less than 10% of body surface area (BSA) * Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%) * No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation \[PUVA\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids) * Known active human immunodeficiency virus (HIV) infection (defined as patients who are not on anti-retroviral treatment and have detectable viral load and CD4+ \< 500/ml) * NOTE: HIV-positive patients who are well controlled on anti-retroviral therapy are allowed to enroll * History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted * Severe infections =\< 4 weeks prior to registration, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia * History of peripheral neuropathy \>= grade 2 * Known hypersensitivity to docetaxel or polysorbate 80
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) of Bintrafusp Alfa in Combination With Docetaxel Versus (vs) Docetaxel Alone | From randomization to the first of either disease progression or death from any cause, assessed up to 3 years and 2 months | The primary analysis of PFS will be a comparison of the Kaplan-Meier curves for docetaxel + bintrafusp alfa vs. docetaxel alone using a one-sided log-rank test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From study entry to death from any cause, assessed up to 3 years and 2 months | OS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
| Confirmed Response Rates | Up to 3 years and 2 months | Will be classified as a confirmed response per the Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST) criteria, if they have a partial or complete response for 2 consecutive evaluations at least 4 weeks apart. The proportion of patients with a confirmed response will be calculated and compared between the 2 arms using a Chi-square of Fisher's Exact test. |
| Duration of Response | Up to 3 years and 2 months | The duration of confirmed responses will be assessed using the Kaplan Meier method, where the duration of confirmed response will be defined as the time from the first documented date of response (complete response \[CR\] or partial response \[PR\]) to the date at which progression is first documented. Duration of response will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
| Incidence of Adverse Events | Up to 3 years and 2 months | The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Countries
United States
Participant flow
Recruitment details
Study was projected to accrue 80 patients and only accrued 10 due to early termination of study.
Participants by arm
| Arm | Count |
|---|---|
| Arm I (Docetaxel, Bintrafusp Alfa) Patients receive docetaxel IV over 1 hour and bintrafusp alfa IV over 60 minutes on day 1. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bintrafusp alfa IV over 60 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.\>\> \>\> Bintrafusp Alfa: Given IV\>\>
\>\> Docetaxel: Given IV | 6 |
| Arm II (Docetaxel) Patients receive docetaxel IV over 1 hour on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may crossover to Arm I and receive bintrafusp alfa alone.\>\>
\>\> Docetaxel: Given IV | 3 |
| Total | 9 |
Baseline characteristics
| Characteristic | Arm I (Docetaxel, Bintrafusp Alfa) | Arm II (Docetaxel) | Total |
|---|---|---|---|
| Age, Continuous | 64.8 years STANDARD_DEVIATION 7.44 | 69.0 years STANDARD_DEVIATION 8.72 | 66.2 years STANDARD_DEVIATION 7.61 |
| ECOG Performance Status 0 | 4 Participants | 1 Participants | 5 Participants |
| ECOG Performance Status 1 | 2 Participants | 2 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants | 3 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| MedDRA Disease Code Lung adenocarcinoma | 6 Participants | 0 Participants | 6 Participants |
| MedDRA Disease Code Non-small cell lung cancer, NOS | 0 Participants | 2 Participants | 2 Participants |
| MedDRA Disease Code Squamous cell lung carcinoma | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 6 Participants | 3 Participants | 9 Participants |
| Sex: Female, Male Female | 2 Participants | 0 Participants | 2 Participants |
| Sex: Female, Male Male | 4 Participants | 3 Participants | 7 Participants |
| Smoking Status Current | 0 Participants | 1 Participants | 1 Participants |
| Smoking Status Former | 3 Participants | 1 Participants | 4 Participants |
| Smoking Status Never | 3 Participants | 1 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 1 / 3 | 0 / 1 |
| other Total, other adverse events | 3 / 6 | 1 / 3 | 0 / 1 |
| serious Total, serious adverse events | 0 / 6 | 1 / 3 | 0 / 1 |
Outcome results
Primary
Progression-free Survival (PFS) of Bintrafusp Alfa in Combination With Docetaxel Versus (vs) Docetaxel Alone
The primary analysis of PFS will be a comparison of the Kaplan-Meier curves for docetaxel + bintrafusp alfa vs. docetaxel alone using a one-sided log-rank test.
Time frame: From randomization to the first of either disease progression or death from any cause, assessed up to 3 years and 2 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I (Docetaxel, Bintrafusp Alfa) | Progression-free Survival (PFS) of Bintrafusp Alfa in Combination With Docetaxel Versus (vs) Docetaxel Alone | 3.0 months |
| Arm II (Docetaxel) | Progression-free Survival (PFS) of Bintrafusp Alfa in Combination With Docetaxel Versus (vs) Docetaxel Alone | 8.6 months |
Secondary
Confirmed Response Rates
Will be classified as a confirmed response per the Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST) criteria, if they have a partial or complete response for 2 consecutive evaluations at least 4 weeks apart. The proportion of patients with a confirmed response will be calculated and compared between the 2 arms using a Chi-square of Fisher's Exact test.
Time frame: Up to 3 years and 2 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Arm I (Docetaxel, Bintrafusp Alfa) | Confirmed Response Rates | 1 Participants |
| Arm II (Docetaxel) | Confirmed Response Rates | 0 Participants |
Secondary
Duration of Response
The duration of confirmed responses will be assessed using the Kaplan Meier method, where the duration of confirmed response will be defined as the time from the first documented date of response (complete response \[CR\] or partial response \[PR\]) to the date at which progression is first documented. Duration of response will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms.
Time frame: Up to 3 years and 2 months
Population: No confirmed response for Arm II.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I (Docetaxel, Bintrafusp Alfa) | Duration of Response | 5.8 months |
Secondary
Incidence of Adverse Events
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test.
Time frame: Up to 3 years and 2 months
Population: Lower grades are better than higher grades
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm I (Docetaxel, Bintrafusp Alfa) | Incidence of Adverse Events | Grade 3+ Adverse Event | 3 Participants |
| Arm I (Docetaxel, Bintrafusp Alfa) | Incidence of Adverse Events | Grade 3+ Heme Adverse Event | 3 Participants |
| Arm I (Docetaxel, Bintrafusp Alfa) | Incidence of Adverse Events | Grade 3+ Non-Heme Adverse Event | 2 Participants |
| Arm I (Docetaxel, Bintrafusp Alfa) | Incidence of Adverse Events | Grade 4+ Adverse Event | 3 Participants |
| Arm I (Docetaxel, Bintrafusp Alfa) | Incidence of Adverse Events | Grade 4+ Heme Adverse Event | 3 Participants |
| Arm I (Docetaxel, Bintrafusp Alfa) | Incidence of Adverse Events | Grade 4+ Non-Heme Adverse Event | 0 Participants |
| Arm II (Docetaxel) | Incidence of Adverse Events | Grade 4+ Heme Adverse Event | 2 Participants |
| Arm II (Docetaxel) | Incidence of Adverse Events | Grade 3+ Adverse Event | 3 Participants |
| Arm II (Docetaxel) | Incidence of Adverse Events | Grade 4+ Adverse Event | 3 Participants |
| Arm II (Docetaxel) | Incidence of Adverse Events | Grade 3+ Heme Adverse Event | 2 Participants |
| Arm II (Docetaxel) | Incidence of Adverse Events | Grade 4+ Non-Heme Adverse Event | 1 Participants |
| Arm II (Docetaxel) | Incidence of Adverse Events | Grade 3+ Non-Heme Adverse Event | 3 Participants |
Secondary
Overall Survival (OS)
OS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms.
Time frame: From study entry to death from any cause, assessed up to 3 years and 2 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm I (Docetaxel, Bintrafusp Alfa) | Overall Survival (OS) | 22.0 months |
| Arm II (Docetaxel) | Overall Survival (OS) | 16.3 months |